Epilepsy
≈ 32 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Epilepsy is a group of neurological disorders characterized by a tendency for recurrent, unprovoked seizures. A seizure is a sudden burst of abnormal electrical activity in the brain that can cause a variety of symptoms, ranging from brief lapses of awareness or muscle jerks to prolonged convulsions. These episodes can result in physical injuries, either directly, such as broken bones, or through causing accidents. The diagnosis of epilepsy typically requires at least two unprovoked seizures occurring more than 24 hours apart. In some cases, it may be diagnosed after a single unprovoked seizure if clinical evidence suggests a high risk of recurrence. Isolated seizures that occur without recurrence risk or are provoked by identifiable causes are not considered indicative of epilepsy. The underlying cause is often unknown, but epilepsy can result from brain injury, stroke, infections, tumors, genetic conditions, developmental abnormalities, trauma, drowning, or an unidentified medical condition. In most cases, no structural or toxicological cause of death is found at autopsy. SUDEP can occur with or without evidence of a preceding seizure, and is often unwitnessed, especially during sleep. Epilepsy that occurs as a result of other issues may be preventable.…
Epilepsy is a group of neurological disorders characterized by a tendency for recurrent, unprovoked seizures. A seizure is a sudden burst of abnormal electrical activity in the brain that can cause a variety of symptoms, ranging from brief lapses of awareness or muscle jerks to prolonged convulsions. These episodes can result in physical injuries, either directly, such as broken bones, or through causing accidents. The diagnosis of epilepsy typically requires at least two unprovoked seizures occurring more than 24 hours apart. In some cases, it may be diagnosed after a single unprovoked seizure if clinical evidence suggests a high risk of recurrence. Isolated seizures that occur without recurrence risk or are provoked by identifiable causes are not considered indicative of epilepsy. The underlying cause is often unknown, but epilepsy can result from brain injury, stroke, infections, tumors, genetic conditions, developmental abnormalities, trauma, drowning, or an unidentified medical condition. In most cases, no structural or toxicological cause of death is found at autopsy. SUDEP can occur with or without evidence of a preceding seizure, and is often unwitnessed, especially during sleep. Epilepsy that occurs as a result of other issues may be preventable. Diagnosis involves ruling out other conditions that can resemble seizures, and may include neuroimaging, blood tests, and electroencephalography (EEG). Most cases of epilepsy, approximately 69%, can be effectively controlled with anti-seizure medications, and inexpensive treatment options are widely available. For those whose seizures do not respond to drugs, other approaches, such as surgery, neurostimulation or dietary changes, may be considered. Not all cases of epilepsy are lifelong, and many people improve to the point that treatment is no longer needed. , approximately 50 million people worldwide have epilepsy, with nearly 80% of cases occurring in low- and middle-income countries. The burden of epilepsy in low-income countries is more than twice that in high-income countries, likely due to higher exposure to risk factors such as perinatal injury, infections, and traumatic brain injury, combined with limited access to healthcare. In 2021, epilepsy was responsible for an estimated 140,000 deaths, an increase from 125,000 in 1990. Epilepsy is more common in both children and older adults. About 5–10% of people will have an unprovoked seizure by the age of 80. The chance of experiencing a second seizure within two years after the first is around 40%. People with epilepsy may be treated differently in various areas of the world and experience varying degrees of social stigma due to the alarming nature of their symptoms. In many countries, people with epilepsy face driving restrictions and must be seizure-free for a set period before regaining eligibility to drive. The word epilepsy is from Ancient Greek , 'to seize, possess, or afflict'.
Signs and symptoms
Epilepsy is characterized by a long-term tendency to experience recurrent, unprovoked seizures. They may vary widely in their presentation depending on the affected brain regions, age of onset, and type of epilepsy.
Seizures
According to the 2025 classification by the International League Against Epilepsy (ILAE), seizures are grouped into four main classes: focal, generalized, unknown (whether focal or generalized), and unclassified.
Postictal state
After the active portion of a seizure (the ictal state) there is typically a period of recovery during which there is confusion, referred to as the postictal state, before a normal level of consciousness returns, lasting minutes to days. This period is marked by confusion, headache, fatigue, or speech and motor disturbances. Some may experience Todd's paralysis, a transient focal weakness. Postictal psychosis occurs in approximately 2% of individuals with epilepsy, particularly after clusters of generalized tonic–clonic seizures.
Psychosocial
Epilepsy can have substantial effects on psychological and social well-being. People with the condition may experience social isolation, stigma, or functional disability, which can contribute to lower educational attainment and reduced employment opportunities. These challenges often extend to family members, who may also encounter stigma and increased caregiving burden. Several psychiatric and neurodevelopmental disorders are more common in individuals with epilepsy. These include depression, anxiety, obsessive–compulsive disorder (OCD), and migraine. Attention deficit hyperactivity disorder (ADHD) is particularly prevalent among children with epilepsy, occurring three to five times more often than in the general population. ADHD and epilepsy together can markedly affect behavior, learning, and social development. Epilepsy is also more common in children with autism spectrum disorder. Approximately, one-in-three people with epilepsy have a lifetime history of a psychiatric disorder. This association is thought to reflect a combination of shared neurobiological mechanisms and the psychosocial impact of living with a chronic neurological condition. Some research also suggests that psychiatric conditions such as depression may precede the onset of epilepsy in certain individuals, particularly those with focal epilepsy. The nature of this association remains under investigation and may involve shared pathways, diagnostic overlap, or other confounding factors. According to Director of the Epilepsy and Clinical Neurophysiology Division and William G. Lennox Chair in the Department of Neurology at Boston Children's Hospital Phillip L. Pearl's research in epilepsy, particularly within inherited metabolic epilepsies such as succinic semialdehyde dehydrogenase deficiency (SSADHD), has emphasized the disorder as a systems-level neurophysiological condition rather than a purely seizure-centric entity. Comorbid depression and anxiety are associated with poorer quality of life, increased healthcare utilization, reduced treatment response (including to surgery), and higher mortality. Some studies suggest that these psychiatric conditions may influence quality of life more than seizure type or frequency. Despite their clinical importance, depression and anxiety often go underdiagnosed and undertreated in people with epilepsy.
Genetics
Genetic causes of epilepsy are those in which a person's genes directly contribute to the development of seizures. This includes cases where a specific mutation has been identified, as well as situations where the family history and clinical features strongly suggest a genetic basis, even if no known mutation is found. In the updated classification by the ILAE, the term genetic replaces the older term idiopathic. Genetic factors can contribute either directly or by increasing vulnerability to other causes. Around 1–2% of cases are caused by a single gene defect, while most are due to a combination of multiple genes and environmental influences. Many of the genes known to play a role in epilepsy affect how brain cells send electrical signals, especially those involved in ion channels, receptors or signaling proteins. Extensive screening have failed to identify many single gene variants of large effect. More recent exome and genome sequencing studies have begun to reveal a number of de novo mutations that are responsible for some epileptic encephalopathies, including CHD2 and SYNGAP1 and DNM1, GABBR2, FASN and RYR3. Some genetic disorders, including phakomatoses such as tuberous sclerosis complex and Sturge–Weber syndrome are strongly associated with epilepsy.
Immune
Immune causes include conditions like autoimmune encephalitis, in which the immune system attacks brain tissue, often presenting with seizures. Certain autoimmune epilepsies are associated with specific autoantibodies, including those against the NMDA receptor, LGI1 and CASPR2. These cases often present with rapid-onset, difficult-to-treat seizures. Celiac disease has also been associated with epilepsy in rare syndromic forms, such as the triad of epilepsy, cerebral calcifications, and celiac disease.
Diagnosis
The diagnosis of epilepsy is primarily clinical, based on a thorough evaluation of the person's history, seizure features, and risk of recurrence. Diagnostic tests such as electroencephalograms and neuroimaging can support the diagnosis. Clinicians must also distinguish epileptic seizures from other conditions that can mimic them and determine whether the event was provoked by an acute, reversible cause or if it suggests a long-term tendency for unprovoked seizures.
Definition
According to the International League Against Epilepsy (ILAE), a diagnosis of epilepsy can be made when any one of the following criteria is met: The ILAE also introduced the concept of resolved epilepsy, which applies to individuals who are past the typical age range for an age-dependent syndrome, or who have remained seizure-free for at least 10 years, including the last 5 years without medication. This 2014 practical definition built upon the broader 2005 conceptual framework, which defined epilepsy as a disorder involving an enduring predisposition to generate epileptic seizures. The updated criteria incorporated recurrence risk and reflected the realities of clinical decision-making. While widely adopted in clinical settings, other definitions, such as the traditional "two unprovoked seizures" rule still used by the World Health Organization, remain appropriate in epidemiology and public health contexts, provided they are clearly stated. The 2014 revision also changed its terminology, referring to epilepsy as a disease rather than a disorder.
Classification
Once epilepsy is diagnosed, the ILAE recommends a three-level framework to guide further classification and management: Identify the seizure type, based on clinical features and EEG (e.g., focal aware seizure, generalized absence) Determine the epilepsy type, such as focal, generalized, combined, or unknown Identify an epilepsy syndrome, if applicable Not all levels can always be determined; in some cases, only the seizure type is identifiable. The etiology (whether structural, genetic, infectious, metabolic, immune, or unknown) should be considered at each stage of classification, as it often influences treatment and prognosis. The classification of epilepsies has evolved over time. Earlier systems emphasized seizure location and used terms such as "partial" or "cryptogenic," which have been replaced in the modern framework. The current system, introduced in 2017, was proposed to reflect advances in neuroimaging, genetics, and in the clinical understanding of the condition.
Syndromes
An epilepsy syndrome is a specific diagnosis based on a combination of features, including seizure types, age of onset, EEG patterns, imaging findings, and associated symptoms or comorbidities. In many cases, a known genetic or structural cause may also support the diagnosis. Some syndromes are self-limited and age-dependent, such as childhood absence epilepsy, juvenile myoclonic epilepsy, and self-limited epilepsy with centrotemporal spikes, and typically respond well to treatment or remit with age. In contrast, more severe syndromes fall under the category of developmental and epileptic encephalopathies (DEEs). These include Lennox–Gastaut syndrome, West syndrome, Rasmussen syndrome and Dravet syndrome, which typically present in early childhood with drug-resistant seizures and are associated with significant neurodevelopmental impairments. Some epilepsy syndromes do not yet fit neatly within current etiological categories, particularly when no definitive cause has been identified. In many cases, a genetic cause is presumed based on age of onset, family history, and electroclinical features, even if no mutation has been found.
Tests
can aid in locating the focus of the epileptic seizure. The diagnostic evaluation of epilepsy begins with a detailed clinical history, supported by eyewitness accounts and, when available, video recordings, to confirm whether the reported event was a seizure and distinguish it from common mimics such as non-epileptic seizures. Following clinical evaluation, selected tests including a sleep study may be used to rule out acute causes and seizure mimics. A 12-lead electrocardiogram (ECG) is recommended for all individuals presenting with a first seizure, to screen for cardiac arrhythmias and other cardiovascular conditions that may resemble epilepsy. Blood tests may be performed to identify metabolic disturbances such as hypoglycemia, electrolyte imbalances, or renal and hepatic dysfunction, particularly in acute settings. Once epilepsy is suspected, electroencephalography (EEG) is used to support the diagnosis. A routine EEG may include activation techniques such as hyperventilation or photic stimulation. However, a normal EEG does not rule out epilepsy. When initial EEG findings are inconclusive, prolonged monitoring techniques such as ambulatory or video EEG may be necessary, including sleep-deprived recordings. Neuroimaging, usually with magnetic resonance imaging (MRI), is recommended to detect structural causes of epilepsy. If MRI is contraindicated or unavailable, computed tomography (CT) may be considered. Additional tests may be guided by clinical context. Genetic testing may be considered in individuals with early-onset epilepsy, developmental delay and/or features of a known genetic epilepsy syndrome. Testing for neuronal antibodies may be appropriate in suspected cases of autoimmune encephalitis, particularly when seizures are new-onset, progressive and/or treatment-resistant. Metabolic testing may be pursued in infants or children with unexplained epilepsy, especially when developmental regression or multisystem involvement is present. Serum prolactin may occasionally be measured after a suspected seizure, particularly to help distinguish epileptic seizures from non-epileptic events. While it can be elevated following certain seizure types, the test lacks sufficient sensitivity and specificity and is not recommended for routine use.
Differential diagnosis
Several conditions can resemble epileptic seizures and are collectively referred to as non-epileptic seizures. Common mimics include fainting (syncope), psychogenic non-epileptic seizures (PNES), transient ischemic attacks, migraine, narcolepsy, and various sleep or movement disorders. In children, events such as reflux, breath-holding spells, parasomnias and others may resemble seizures. Psychogenic non-epileptic seizures (PNES) are involuntary episodes that resemble epileptic seizures but are not associated with abnormal electrical discharges. They are classified as functional neurological disorders and are typically associated with psychological distress or trauma. Studies suggest that approximately 20% of individuals referred to epilepsy centers are diagnosed with PNES, and up to 10% of these individuals also have coexisting epilepsy. Differentiating between the two can be difficult and often requires prolonged video EEG monitoring. Misdiagnosis remains a significant concern in epilepsy. Reported rates vary widely, from 2% to 71%, depending on factors such as clinical setting, patient population, diagnostic criteria and physician expertise.
Prevention
Although many causes of epilepsy are not preventable, several known risk factors are modifiable. Perinatal care can lower the risk of epilepsy in infants. Vaccination programs, especially against neurotropic infections such as measles and meningitis, play a key role in preventing epilepsy caused by central nervous system infections. In low- and middle-income countries, neurocysticercosis remains a major preventable cause of epilepsy, which can be reduced through improved sanitation and food safety. Eliminating or reducing risk factors for seizures in older adults such as inactivity, smoking, diabetes, high blood pressure, and excessive alcohol consumption have been suggested as strategies to help prevent epilepsy in older adults.
Management
The primary goals of epilepsy management are to control seizures, minimize treatment side effects, and optimize quality of life. Management strategies are individualized based on the type of seizures or epilepsy syndrome, the underlying cause when known, the person's age and comorbidities, and their preferences and life circumstances. Supporting people's self-management of their condition may be useful. In drug-resistant cases, different management options may be considered, including special diets, the implantation of a neurostimulator, or neurosurgery.
First aid and acute management of seizures
During a generalized tonic–clonic seizure, the primary goals are to ensure safety and prevent injury. The following steps should be taken: Stay calm and remove any potential hazards from the area. Clear the space of sharp objects, furniture, or anything that might cause injury. If the person is standing, gently guide them to the ground to avoid a fall. Position the person on their side and into the recovery position, which helps keep the airway clear and reduces the risk of choking. If possible, place something soft (e.g., a jacket or cushion) under their head to prevent injury. Do not restrain their movements or attempt to hold them down. Do not put anything in their mouth, as this may cause harm. If the seizure lasts longer than 5 minutes or if multiple seizures occur without full recovery in between, it is important to call for emergency medical assistance immediately, as it is considered a medical emergency known as status epilepticus. Convulsive status epilepticus requires immediate medical attention to prevent serious complications. In a community setting (such as at home or in the ambulance), first-line treatment includes the administration of benzodiazepines. If the person has an individualized emergency management plan, which may have been developed with healthcare providers and outlines personalized treatment steps (such as the use of buccal midazolam or rectal diazepam), this plan should be followed immediately. In hospital, intravenous lorazepam is preferred. If seizures continue after the first dose of benzodiazepine, emergency medical services should be contacted, and further doses can be given. For ongoing seizures, levetiracetam, phenytoin, or sodium valproate may be used as second-line treatments, with levetiracetam preferred for its quicker action and fewer side effects. Most institutions have a preferred pathway or protocol to be used in a seizure emergency like status epilepticus. These protocols have been found to be effective in reducing time to delivery of treatment.
Medications
The primary treatment for epilepsy involves the use of antiseizure medications (ASMs), which aim to control seizures while minimizing side effects. Treatment plans should be individualized, taking into account the seizure type, epilepsy syndrome, patient age, sex, comorbidities, lifestyle factors, and the potential for drug interactions. First-line treatment for most individuals with epilepsy is monotherapy with a single ASM. For many people with epilepsy, seizure control is achieved with a single medication, but some may require combination therapy if seizures are not well-controlled with monotherapy. There are a number of medications available including phenytoin, carbamazepine and valproate. Evidence suggests that these drugs are similarly effective for both focal and generalized seizures, although their side-effect profiles vary. Controlled release carbamazepine appears to work as well as immediate release carbamazepine, and may have fewer side effects. In the UK, carbamazepine or lamotrigine are recommended as first-line treatments for focal seizures, with levetiracetam and valproate used as second-line treatments due to concerns about cost and side effects. Valproate is the first-line choice for generalized seizures, while lamotrigine is used as second-line. For absence seizures, ethosuximide or valproate are recommended, with valproate also being effective for myoclonic and tonic–clonic seizures. Controlled-release formulations of carbamazepine may be preferred in some cases, as they appear to be equally effective as immediate-release carbamazepine but may have fewer side effects. Once a person's seizures are well-controlled on a specific treatment, it is generally not necessary to routinely check medication blood levels, unless there are concerns about side effects or toxicity. In low- and middle-income countries (LMICs), the management of epilepsy is often hindered by limited access to medications, diagnostic tools, and specialized care. While phenytoin and carbamazepine are commonly used as first-line treatments due to their availability and low cost, newer drugs like levetiracetam and lamotrigine may not be accessible. Additionally, surgical options and advanced therapies, such as vagus nerve stimulation or resective surgery, are typically inaccessible due to high costs and lack of infrastructure. The least expensive anticonvulsant is phenobarbital at around US$5 a year. The World Health Organization gives it a first-line recommendation in LMICs and it is commonly used in these countries. Access, however, may be difficult as some countries label it as a controlled drug. Adverse effects from medications are reported in 10% to 90% of people, depending on how and from whom the data is collected. Most adverse effects are dose-related and mild. Some examples include mood changes, sleepiness, or an unsteadiness in gait. Certain medications have side effects that are not related to dose such as rashes, liver toxicity, or suppression of the bone marrow. Up to a quarter of people stop treatment due to adverse effects. Some medications are associated with birth defects when used in pregnancy. Many of the common used medications, such as valproate, phenytoin, carbamazepine, phenobarbital, and gabapentin have been reported to cause increased risk of birth defects, especially when used during the first trimester. Despite this, treatment is often continued once effective, because the risk of untreated epilepsy is believed to be greater than the risk of the medications. Among the antiepileptic medications, levetiracetam and lamotrigine seem to carry the lowest risk of causing birth defects. Gradually stopping medications may be considered by a physician in some people who have been seizure-free for two to four years. Around a third of patients have a recurrence, most often during the first six months. Stopping is possible in about 70% of children and 60% of adults. Measuring medication levels is not generally needed in those whose seizures are well controlled.
Surgery
Epilepsy surgery is a treatment option for individuals with drug-resistant epilepsy, typically defined as the failure of at least two appropriately chosen and tolerated antiseizure medications. Surgery is most effective in cases of focal epilepsy, where seizures originate from a specific area of the brain that can be safely removed. Epilepsy surgery remains underutilized worldwide and is often reserved for individuals whose condition has reached an advanced or chronic stage. This evaluation, conducted in specialized epilepsy centers, includes seizure classification, long-term video EEG monitoring, high-resolution MRI with epilepsy-specific protocols, neuropsychological assessment, and sometimes functional imaging or invasive monitoring. Early referral improves the likelihood of successful outcomes and avoids prolonged periods of unnecessary disability. The primary goal of epilepsy surgery is to achieve seizure freedom, but even when that is not possible, palliative procedures that significantly reduce seizure frequency can lead to meaningful improvements in quality of life and development, particularly in children. Studies suggest that 60-70% of individuals with drug-resistant focal epilepsy experience a substantial reduction in seizures following surgery. Common procedures include anterior temporal lobe resection, which often involves removal of the hippocampus in cases of mesial temporal lobe epilepsy, as well as lesionectomy for tumors or cortical dysplasia, and lobectomy for larger seizure foci. In cases where resection is not possible, procedures such as corpus callosotomy may help reduce the severity and spread of seizures. In addition to traditional resective techniques, minimally invasive approaches such as MRI-guided laser interstitial thermal therapy (LITT) have gained traction as safer alternatives in select cases, particularly where reducing cognitive impact and recovery time is a priority. In many cases, antiseizure medications can be tapered following successful surgery, though long-term monitoring remains essential. Surgical treatment is not limited to adults. A 2023 systematic review found that early surgery in children under 3 years with drug-resistant epilepsy can result in meaningful seizure reduction or freedom when other treatments have failed.
Diet
Dietary therapy, particularly the ketogenic diet (high-fat, low-carbohydrate, adequate-protein), is a non-pharmacological treatment option used primarily in children with drug-resistant epilepsy. Evidence suggests that children on a classical ketogenic diet may be up to three times more likely to achieve seizure freedom and up to six times more likely to experience a ≥50% reduction in seizure frequency compared to those receiving standard care. Modified versions of the diet, such as the modified Atkins diet, are better tolerated but may be less effective. In adults, the ketogenic diet has shown limited evidence of achieving seizure freedom, though it may increase the likelihood of seizure reduction. However, further research is necessary. It is typically supervised by a multidisciplinary team, including neurologists and dietitians, due to its restrictive nature and potential side effects, such as vomiting, constipation and diarrhoea. Regular monitoring of nutritional status, blood parameters, and growth is recommended. It is unclear why this diet works. The diet leads to an increased elevation of plasma decanoic acid and ketones. However, some research is giving the indication that it may be the decanoic acid that is anti-convulsant. A gluten-free diet has been proposed in rare cases of epilepsy associated with celiac disease and occipital calcifications, though evidence is limited and based on small case series.
Prognosis
Epilepsy is generally considered a chronic neurological condition. Its long-term course can vary widely depending on factors such as seizure type, underlying cause, and response to treatment. Although epilepsy is not typically "cured," in many cases it may be considered resolved. According to the ILAE, epilepsy is considered to be resolved in individuals who have been seizure-free for at least 10 years, with no antiseizure medications for the last 5 of those years. Approximately 60–70% of individuals with epilepsy achieve good seizure control with appropriate antiseizure medications, and many can maintain long-term remission. Outcomes vary by epilepsy type and etiology. Early treatment response is one of the strongest predictors of long-term outcome, with poor early control correlating with lower chances of remission. Several factors, such as structural brain abnormalities, comorbid developmental disorders, and/or a high frequency of seizures at onset, have been associated with worse outcomes, although findings are not always consistent. Epilepsy disproportionately affects low- and middle-income countries, where nearly 80% of the global epilepsy population resides. In these countries, up to 75% of individuals with epilepsy do not receive the treatment they need. Untreated epilepsy is associated with elevated risk of injury, psychiatric comorbidities, and early death, including sudden unexpected death in epilepsy (SUDEP).
Cognition
Cognitive impairment frequently accompanies epilepsy, although it is difficult to determine to what extant it is caused by the epilepsy itself. This is because observed cognitive decline could be a result of the cause of the epilepsy (e.g. epilepsy caused by mesial temporal sclerosis), or be secondary to the epilepsy (e.g. brain damage from falling due to a seizure, or impairment from pharmacological or surgical treatment of the epilepsy). In the majority of people who achieve seizure control, there is no associated progressive cognitive decline. However, severe intractable epilepsy is associated with negative cognitive effects. Due to its variability, it is unclear whether any given case of epilepsy will lead to cognitive decline, but a few points are noted: Epilepsy is associated with increased risk for Alzheimer's disease (and vice-versa). Longer seizures cause more damage than shorter seizures. Progressive thinning of the cerebral cortex occurs with recurring seizures.
Mortality
People with epilepsy may have a higher risk of premature death compared to those without the condition. This risk is estimated to be between 1.6 and 4.1 times greater than that of the general population. The greatest increase in mortality from epilepsy is among the elderly. Those with epilepsy due to an unknown cause have a relatively low increase in risk. Mortality is often related to the underlying cause of the seizures, status epilepticus, suicide, trauma, and sudden unexpected death in epilepsy (SUDEP). Death from status epilepticus is primarily due to an underlying problem rather than missing doses of medications. The risk of suicide is between two and six times higher in those with epilepsy; the cause of this is unclear. SUDEP appears to be partly related to the frequency of generalized tonic-clonic seizures and accounts for about 15% of epilepsy-related deaths; it is unclear how to decrease its risk. Risk factors for SUDEP include nocturnal generalized tonic-clonic seizures, seizures, sleeping alone and medically intractable epilepsy. In the United Kingdom, it is estimated that 40–60% of deaths are possibly preventable. In the developing world, many deaths are due to untreated epilepsy leading to falls or status epilepticus.
Epidemiology
Epilepsy is one of the most common serious neurological disorders, affecting approximately 50 million people globally as of 2021, with the majority living in low- and middle-income countries. The point prevalence of active epilepsy is generally reported between 5 and 7 per 1,000 people, while lifetime prevalence is slightly higher, typically between 6 and 9 per 1,000. Both prevalence and incidence are higher in low-income regions. The annual incidence of epilepsy (the rate of new diagnoses each year) is estimated at 50 to 70 new cases per 100,000 people1 globally, based on population studies. Rates are significantly higher in low- and middle-income countries, and, within high-income countries, higher incidence has also been observed among lower socioeconomic groups and some ethnic minorities. Epilepsy can develop at any age, but its incidence is highest in early infancy and in older adults, following a bimodal distribution. In high-income countries, the incidence peaks during the first year of life, declines during adulthood, and rises again in people over age 85. The increase in older adults is associated with age-related conditions such as stroke, brain tumors, and neurodegenerative diseases. In low- and middle-income countries, incidence more often peaks in older children and young adults. Epilepsy is slightly more common in males than females, a difference that may be associated with risk factor exposure and underreporting in women in some regions due to sociocultural factors. Epilepsy is responsible for an estimated 13 million disability-adjusted life years (DALYs) worldwide each year, with the majority of this burden falling on individuals in low-resource settings where access to diagnosis and treatment remains limited.
History
of an antique bust The oldest medical records show that epilepsy has been affecting people at least since the beginning of recorded history. Throughout ancient history, the condition was thought to be of a spiritual cause. The world's oldest description of an epileptic seizure comes from a text in Akkadian (a language used in ancient Mesopotamia) and was written around 2000 BC. The person described in the text was diagnosed as being under the influence of a moon god, and underwent an exorcism. Epileptic seizures are listed in the Code of Hammurabi ( ) as reason for which a purchased slave may be returned for a refund, and the Edwin Smith Papyrus ( ) describes cases of individuals with epileptic convulsions. The oldest known detailed record of the condition itself is in the Sakikku, a Babylonian cuneiform medical text from 1067 1046 BC. This text gives signs and symptoms, details treatment and likely outcomes, and describes many features of the different seizure types. As the Babylonians had no biomedical understanding of the nature of epilepsy, they attributed the seizures to possession by evil spirits and called for treating the condition through spiritual means. Around 900 BC, Punarvasu Atreya described epilepsy as loss of consciousness; this definition was carried forward into the Ayurvedic text of Charaka Samhita ( ). The ancient Greeks had contradictory views of the condition. They thought of epilepsy as a form of spiritual possession, but also associated the condition with genius and the divine. One of the names they gave to it was the sacred disease ( ). Epilepsy appears in Greek mythology: it is associated with the Moon goddesses Selene and Artemis, who afflicted those who upset them. The Greeks thought that important figures such as Julius Caesar and Hercules had the condition. The notable exception to this divine and spiritual view was that of the school of Hippocrates. In the fifth century BC, Hippocrates rejected the idea that the condition was caused by spirits. In his landmark work On the Sacred Disease, he proposed that epilepsy was not divine in origin and instead was a medically treatable problem originating in the brain. He accused those of attributing a sacred cause to the condition of spreading ignorance through a belief in superstitious magic. Hippocrates proposed that heredity was important as a cause, described worse outcomes if the condition presents at an early age, and made note of the physical characteristics as well as the social shame associated with it. Instead of referring to it as the sacred disease, he used the term great disease, giving rise to the modern term grand mal, used for tonic–clonic seizures. Despite his work detailing the physical origins of the condition, his view was not accepted at the time. Evil spirits continued to be blamed until at least the 17th century. Menecrates of Syracuse was famous for healing the sacred disease. In Ancient Rome people did not eat or drink with the same pottery as that used by someone who was affected. People of the time would spit on their chest believing that this would keep the problem from affecting them. According to Apuleius and other ancient physicians, to detect epilepsy, it was common to light a piece of gagates, whose smoke would trigger the seizure. Occasionally a spinning potter's wheel was used, perhaps a reference to photosensitive epilepsy. In most cultures, persons with epilepsy have been stigmatized, shunned, or even imprisoned. As late as in the second half of the 20th century, in Tanzania and other parts of Africa epilepsy was associated with possession by evil spirits, witchcraft, or poisoning and was believed by many to be contagious. In the Salpêtrière, the birthplace of modern neurology, Jean-Martin Charcot found people with epilepsy side by side with the mentally ill, those with chronic syphilis, and the criminally insane. In Ancient Rome, epilepsy was known as the or 'disease of the assembly hall' and was seen as a curse from the gods. In northern Italy, epilepsy was traditionally known as Saint Valentine's malady. In at least the 1840s in the United States of America, epilepsy was known as the falling sickness or the falling fits, and was considered a form of medical insanity. Around the same time period, epilepsy was known in France as the , , , , and . People of epilepsy in France were also known as , due to the seizures and loss of consciousness in an epileptic episode. In the mid-19th century, the first effective anti-seizure medication, bromide, was introduced. The first modern treatment, phenobarbital, was developed in 1912, with phenytoin coming into use in 1938.
Society and culture
Beyond its medical impact, epilepsy is associated with social and cultural implications that vary across regions and contexts, including social stigma, legal restrictions, economic disadvantage, barriers to education and unemployment. A large treatment gap persists in many countries, particularly in low- and middle-income settings.
Stigma
Social stigma is commonly experienced by people with epilepsy worldwide. Misconceptions about the condition, including beliefs that it is contagious, a form of madness, or caused by supernatural forces, persist in many communities. In parts of Africa, including Tanzania and Uganda, epilepsy is sometimes associated with spirit possession, witchcraft, poisoning and is incorrectly believed to be contagious. Similar stigmatizing beliefs have been reported in other regions, such as India and China, where epilepsy may be cited as grounds for denying marriage. In the United Kingdom, epilepsy was legally considered valid grounds for annulling a marriage until 1971. Stigma can also affect how people respond to a diagnosis. Some individuals with epilepsy may deny having had seizures, fearing discrimination. A 2024 cross-sectional study found that 64.8% of relatives of people with epilepsy reported experiencing moderate levels of stigma, which was associated with more negative attitudes toward the condition. Greater stigma was observed among relatives of patients with more frequent seizures or poor medication adherence. Negative perceptions of epilepsy can also affect educational opportunities and academic outcomes. In adulthood, stigma can also result in reduced employment opportunities and workplace discrimination. Adults with epilepsy are more likely to be unemployed or underemployed than the general population. Disclosure of an epilepsy diagnosis in job applications or interviews may lead to discrimination, although nondisclosure can limit access to workplace accommodations.
Research directions
Epilepsy research spans the investigation of seizure mechanisms, improvements in diagnosis, and the development of new treatments, including efforts to understand and prevent epileptogenesis.
Seizure prediction
The unpredictability of seizures is a major concern for many people with epilepsy, and seizure prediction has been a longstanding focus of research. Early efforts were limited by small datasets and inconsistent results; however, advances in computational modeling, long-term EEG recording, and machine learning have led to renewed interest in the field. Public EEG databases and algorithm competitions have helped standardize evaluation and fostered the development of more accurate methods. In one clinical trial, prospective seizure prediction using intracranial EEG was achieved in a small group of participants. Current approaches often integrate network models of brain activity, multimodal data sources and closed-loop systems capable of both detecting and responding to pre-ictal changes.
Potential future therapies
Several novel therapeutic strategies are under investigation for epilepsy. Gene therapy is being studied in some types of epilepsy. Medications that alter immune function, such as intravenous immunoglobulins, may reduce the frequency of seizures when including in normal care as an add-on therapy; however, further research is required to determine whether these medications are very well tolerated in children and in adults with epilepsy. Noninvasive stereotactic radiosurgery is, , being compared to standard surgery for certain types of epilepsy.
Other animals
Epilepsy has also been documented in several animal species, particularly dogs and cats. Veterinary treatments often use similar antiepileptic drugs, such as phenobarbital or levetiracetam. In horses, diagnosis can be challenging, especially in focal seizures, and such conditions as juvenile idiopathic epilepsy have been reported in foals.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378423147 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “Epilepsy” population (×1) · confidence 0.95 revision URL